Updated on 2025/02/22

写真a

 
SHIBATA ATSUSHI
 
Organization
Graduate School of Medicine Department of Clinical Medical Science Lecturer
School of Medicine Department of Medical Science
Title
Lecturer
Affiliation
Institute of Medcine

Position

  • Graduate School of Medicine Department of Clinical Medical Science 

    Lecturer  2024.04 - Now

  • School of Medicine Department of Medical Science 

    Lecturer  2024.04 - Now

Degree

  • 博士(医学) ( Osaka City University )

Research Areas

  • Life Science / Cardiology

Papers

  • Effect of tafamidis therapy on physical function in patients with wild-type transthyretin cardiac amyloidosis.

    Atsushi Shibata, Yasuhiro Izumiya, Toshitake Yoshida, Akiko Tanihata, Ryoko Kitada, Kenichiro Otsuka, Asahiro Ito, Takanori Yamazaki, Daiju Fukuda

    Journal of cardiology   2024.11( ISSN:09145087

     More details

    Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    BACKGROUND: Tafamidis is used as disease-modifying treatment for patients with wild-type transthyretin cardiac amyloidosis (ATTRwt CA). However, the effects of tafamidis on exercise tolerance are unclear. METHODS: This single-center, prospective, observational study aimed to assess the effect of tafamidis on exercise tolerance in 36 patients with ATTRwt CA. Exercise tolerance was evaluated by the peak oxygen uptake (peak VO2) measured by the cardiopulmonary exercise test (CPX). RESULTS: The baseline CPX showed a mean anaerobic threshold value of 11.6 ± 2.2 ml/kg/min and peak VO2 of 15.6 ± 4.1 ml/kg/min. Twenty-eight of the 36 patients underwent a follow-up CPX after 6 months. There was no significant change in peak VO2 before and 6 months after tafamidis therapy (16.0 ± 4.2 vs. 14.7 ± 4.0 ml/kg/min). The baseline CPX data showed that the mean peak VO2 was significantly lower in the increased peak VO2 group than in the non-increased peak VO2 group (13.7 ± 3.1 vs. 17.7 ± 4.1 ml/kg/min, p = 0.008). A multivariate logistic regression analysis showed that the baseline peak VO2 value was an independent predictor of improved exercise tolerance by tafamidis therapy (odds ratio: 0.646, 95 % confidence interval: 0.449-0.930, p = 0.019). CONCLUSIONS: Tafamidis prevents deterioration of exercise tolerance in patients with ATTRwt CA. In some patients with ATTRwt CA, exercise tolerance may improve with the use of tafamidis, and those with lower exercise tolerance before tafamidis administration are likely to show improved exercise tolerance.

    DOI: 10.1016/j.jjcc.2024.11.004

    PubMed

  • Severe Left Main Coronary Artery Stenosis and Aortic Regurgitation in a Patient Presenting with Takayasu Arteritis(タイトル和訳中)

    Tanihata Akiko, Shibata Atsushi, Teragaki Kazutoshi, Yoshida Toshitake, Kitada Ryoko, Morisaki Akimasa, Ito Asahiro, Izumiya Yasuhiro, Fukuda Daiju

    Internal Medicine   63 ( 19 )   2641 - 2646   2024.10( ISSN:0918-2918

  • Impact of acute coronary syndrome on early in-stent neoatherosclerosis as shown by optical coherence tomography.

    Kazuhiro Nakao, Takanori Yamazaki, Naoki Fujisawa, Yusuke Kure, Tomohiro Yamaguchi, Shunsuke Kagawa, Takenobu Shimada, Atsushi Shibata, Asahiro Ito, Kenichiro Otsuka, Yasuhiro Izumiya, Daiju Fukuda

    AsiaIntervention   10 ( 3 )   203 - 211   2024.09( ISSN:24263958

     More details

    Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    BACKGROUND: Patients with acute coronary syndrome (ACS) have a higher risk of requiring target vessel revascularisation after percutaneous coronary intervention (PCI) than patients with stable angina. Neoatherosclerosis is a significant risk factor for very late stent thrombosis, and the presence of neoatherosclerosis is independently associated with major adverse cardiac events. AIMS: In this study, we used optical coherence tomography (OCT) to investigate the impact of ACS on neoatherosclerosis within 1 year after PCI. METHODS: We investigated 102 patients (122 lesions) who had undergone PCI using a second-generation drug-eluting stent (DES) from March 2017 to November 2020 and were followed up with OCT within 1 year. The patients were categorised into the ACS group or non-ACS group according to their clinical findings at the time of target lesion treatment. We used OCT to investigate the presence of neoatherosclerosis. RESULTS: The ACS group comprised 23 (22.5%) patients. There were no differences in the patients' clinical characteristics between the groups. The total stent length tended to be shorter in the ACS group than in the non-ACS group (24 mm vs 32 mm, respectively; p=0.09), but this difference was not statistically significant. The median duration from PCI was 290 days. Neoatherosclerosis was more frequent in ACS lesions (39% vs 4%; p<0.01), and implantation of a DES in ACS lesions was an independent predictor of neoatherosclerosis occurrence (odds ratio 9.70; p<0.01). CONCLUSIONS: This observational study using OCT indicates that stenting for ACS lesions is associated with early in-stent neoatherosclerosis.

    DOI: 10.4244/AIJ-D-24-00021

    PubMed

  • Neurological prognosis prediction upon arrival at the hospital after out-of-hospital cardiac arrest: R-EDByUS score

    Shimada T.

    Resuscitation   200   110257   2024.07( ISSN:03009572

  • ヘモグロビンは非虚血性心筋症の男性患者における運動耐容能の改善を予測する独立因子である(Hemoglobin is an independent predictor of improvement exercise tolerance in male patients with non-ischemic cardiomyopathy)

    Tanihata Akiko, Shibata Atsushi, Yoshida Toshitake, Kitada Ryoko, Izumiya Yasuhiro, Fukuda Daiju

    Heart and Vessels   39 ( 5 )   412 - 426   2024.05( ISSN:0910-8327

     More details

    心不全を伴う非虚血性心筋症患者100例を対象に、運動耐容能改善の予測因子について検討した。有意な冠動脈疾患、心筋梗塞の既往、左室駆出率が50%以上の症例は除外した。全例で退院時および6ヵ月後に心肺運動負荷試験を実施した。74例で最高酸素摂取量(peak VO2)の増加を認めた。患者をpeak VO2の増加群74例(男性73.0%、平均58.2±13.4歳)と非増加群26例(男性58.0%、平均64.7±12.4歳)に分類した。ヘモグロビンはpeak VO2の増加群の方が有意に高く、群間差は特に男性で顕著であった。Kaplan-Meier分析で心臓死と心イベントによる再入院を合わせた複合イベントの発症率はpeak VO2の増加群の男性患者の方が非増加群の男性患者に比べて有意に低かった(P=0.032)。また男性患者のヘモグロビンはpeak VO2の増加率と正に相関した(r=0.248、P=0.040)。多変量解析で年齢、左室駆出率、骨格筋量指数を調整した結果、ヘモグロビンは男性患者におけるpeak VO2の増加を予測する独立因子であった(OR:1.60、95%CI:1.05~2.44、P=0.027)。

  • Elevation of end-tidal CO2 during exercise is attenuated in patients with cardiac amyloidosis(タイトル和訳中)

    Shibata Atsushi, Izumiya Yasuhiro, Yoshida Toshitake, Tanihata Akiko, Yamaguchi Yumi, Kitada Ryoko, Fukuda Daiju

    Heart and Vessels   39 ( 4 )   340 - 348   2024.04( ISSN:0910-8327

  • Elevation of end-tidal CO<inf>2</inf> during exercise is attenuated in patients with cardiac amyloidosis

    Shibata A.

    Heart and Vessels   39 ( 4 )   340 - 348   2024.04( ISSN:09108327

  • Hospitalization-Associated Disability Predicts Frailty Progression One Year after Transcatheter Aortic Valve Implantation

    Shimizu Masashi, Shibata Atsushi, Taniguchi Kodai, Kure Yusuke, Okai Tsukasa, Ikebuchi Michihiko, Izumiya Yasuhiro

    Journal of Japanese Cardiovascular Physical Therapy   3 ( 1 )   1 - 12   2024.03( eISSN:27580350

     More details

    <p><b>Aim</b>: The purpose of this study is to investigate factors related to frailty progression at one year after Transcatheter Aortic Valve Implantation (TAVI), including Hospi-talization-Associated Disability (HAD).</p><p><b>Methods</b>: We included 97 patients who underwent transfemoral TAVI (TF-TAVI) and physical therapy intervention at our hospital between February 2019 and March 2021. All patients were evaluated for frailty before and one year after surgery using the Clinical Frailty Scale (CFS). Patients with an increase of at least one point from the preoperative level were classified as frailty progression group and the others as frailty maintenance group. HAD was defined as a decrease in the Barthel Index at discharge compared to before hospitalization. The factors related to frailty progres-sion were evaluated by comparing various clinical indicators, including the occur-rence of HAD, between the two groups.</p><p><b>Results</b>: The occurrence of HAD was significantly higher in the frailty progression group than in the frailty maintenance group (25.0% vs. 8.2%; p=0.035). Furthermore, multivariate logistic regression analysis using frailty progression as the dependent variable and HAD occurrence and other adjusting variables as the independent var-iables showed that HAD occurrence was an independent predictor of frailty progres-sion at one year after the surgery(OR: 5.47, 95%CI: 1.380-21.70; p=0.016).</p><p><b>Conclusion</b>: The occurrence of HAD in patients underwent TF-TAVI is a risk fac-tor for frailty progression at one year after the surgery. </p>

    DOI: 10.69168/jcpt.3.1_1

  • Hemoglobin is an independent predictor of improvement exercise tolerance in male patients with non-ischemic cardiomyopathy. Reviewed

    Akiko Tanihata, Atsushi Shibata, Toshitake Yoshida, Ryoko Kitada, Yasuhiro Izumiya, Daiju Fukuda

    Heart and vessels   39 ( 5 )   412 - 426   2024.02( ISSN:09108327

     More details

    Authorship:Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:Domestic journal  

    Exercise intolerance is a symptom of chronic heart failure (CHF). The magnitude of exercise tolerance, as measured by peak oxygen uptake (peak VO2), is strongly associated with prognosis in patients with CHF. We aimed to evaluate the factors associated with improved exercise tolerance in patients with HF. In this prospective study, we recruited patients who were diagnosed with non-ischemic cardiomyopathy between September 2017 and September 2021. All patients underwent cardiopulmonary exercise testing at discharge and 6 months after enrollment. The patients were stratified according to whether peak VO2 was increased or not at 6 months. One hundred patients with a reduced left-ventricular ejection fraction (LVEF < 50%) were enrolled. Improvement of peak VO2 was observed in 74 patients. In male patients, hemoglobin level was higher in the increased peak VO2 group than in the non-increased group (15.0 ± 1.9 g/dL vs. 13.1 ± 2.1 g/dL; p < 0.01). Baseline hemoglobin level was positively correlated with the percentage change in peak VO2 (Spearman's r = 0.248, p = 0.040). Kaplan-Meier analysis demonstrated that adverse cardiac events were significantly less frequent in the increased peak VO2 group than in the non-increased group (log-rank test, p = 0.032). Multivariate logistic regression analysis identified hemoglobin level as an independent predictor of improved peak VO2 [odds ratio (OR) 1.60; 95% confidence interval (CI) 1.05-2.44; p = 0.027]. Baseline hemoglobin level is an independent predictor of improved peak VO2 in male patients with non-ischemic cardiomyopathy.

    DOI: 10.1007/s00380-024-02358-w

    PubMed

  • Severe Left Main Coronary Artery Stenosis and Aortic Regurgitation in a Patient Presenting with Takayasu Arteritis

    Tanihata Akiko, Shibata Atsushi, Teragaki Kazutoshi, Yoshida Toshitake, Kitada Ryoko, Morisaki Akimasa, Ito Asahiro, Izumiya Yasuhiro, Fukuda Daiju

    Internal Medicine   advpub ( 0 )   2024( ISSN:09182918 ( eISSN:13497235

     More details

    Authorship:Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:Domestic journal  

    <p>We herein report the case of a 46-year-old woman with Takayasu arteritis (TA), severe stenosis in the left main coronary artery (LMCA), and severe aortic regurgitation. Prednisolone and tacrolimus were initiated as TA treatments. Two months after initiating medical therapy, the aortic regurgitation severity improved to a moderate grade, although there was no obvious improvement in LMCA stenosis. Thus, after confirming the resolution of inflammation, we performed coronary artery bypass grafting alone without any aortic valve intervention. In TA patients with severe LMCA stenosis, surgical management of the coronary artery should therefore be considered only after successfully administering anti-inflammatory therapy. </p>

    DOI: 10.2169/internalmedicine.3032-23

    PubMed

▼display all

MISC

  • Changes in Exercise Tolerance in the Subacute Phase after Left Atrial Appendage Closure(タイトル和訳中)

    吉山 智貴, 柴田 敦, 豊田 なつみ, 柳下 知哉, 中逵 賢一, 田村 尚大, 泉家 康宏, 福田 大受

    日本循環器学会学術集会抄録集   88回   PJ068 - 5   2024.03

Presentations

▼display all

Grant-in-Aid for Scientific Research

  • 遺伝子発現制御から検討する拡張型心筋症の病因解明と新規治療法の確立

    Grant-in-Aid for Early-Career Scientists  2025

  • 遺伝子発現制御から検討する拡張型心筋症の病因解明と新規治療法の確立

    Grant-in-Aid for Early-Career Scientists  2024